Cambridge Open Engage home
What is Cambridge Open Engage?
How to Submit
Browse
About
News [opens in a new tab]

[45Ti]Ti-DOTA: En route towards aza-macrocyclic 45Ti-based radiopharmaceuticals

22 April 2024, Version 2
Working Paper
This content is a preprint and has not undergone peer review at the time of posting.

Abstract

We report the first use of DOTA as a chelator for titanium. The resulting complex is fully characterized and extended to the radiolabelling of DOTA with titanium-45.

Keywords

titanium-45
DOTA

Supplementary materials

Title
Description
Actions
Title
Supplementary information
Description
Methods, DFT calculations, Characterization data, Spectra
Actions

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.

Version History

Apr 22, 2024 Version 2

Version Notes

This version includes slight modification from the previous version. Here we have now modified the discussion a bit, based on newly obtained connectivity for Hf-DOTA enantiomers deduced from X-ray crystallography. In supporting information X-ray data have been included along with a new table on geometric parameters for non-capped M-DOTA complexes.

Metrics

583
296
0
Views
Downloads
Citations

License

CC logo
CC
BY logo
BY
NC logo
NC
ND logo
ND
The content is available under CC BY NC ND 4.0 [opens in a new tab]

DOI

10.26434/chemrxiv-2024-0h8z6-v2
D O I: 10.26434/chemrxiv-2024-0h8z6-v2 [opens in a new tab]

Funding

Trond Mohn stiftelse
TMS2019TMT07
Norges Forskningsråd
NN2506K
Norges
NS2506K

Author’s competing interest statement

The author(s) have declared they have no conflict of interest with regard to this content

Ethics

The author(s) have declared ethics committee/IRB approval is not relevant to this content

Share